Chengshui Chen

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Production of <scp>CCL</scp>20 from lung cancer cells induces the cell migration and proliferation through <scp>PI</scp>3K pathway

Beibei Wang, Lin Shi, Xiaoru Sun et al. · Journal of Cellular and Molecular Medicine · 2016 · 96 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Severe Chlamydia psittaci pneumonia: clinical characteristics and risk factors

Shanshan Su, Xiaoqing Su, Lingping Zhou et al. · Annals of Palliative Medicine · 2021 · 52 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +14

STAT1 modification improves therapeutic effects of interferons on lung cancer cells

Junjie Chen, Jialu Zhao, Lefu Chen et al. · Journal of Translational Medicine · 2015 · 39 citations · Full text

Life Sciences, Immunology, Oncology +17